| NL (N = 14) | CA (N = 11) | US (N = 29) | P-value |
---|---|---|---|---|
Time between ethics approval and start trial (days) | 41 (10 - 139) | 232 (98 - 423) | 87 (45 - 255) | 0.027a |
Enrolment period (days) | 423 (381 - 509) | 482 (267 - 663) | 283 (142 - 360) | 0.001b |
Inclusions | 13 (7 - 27) | 3 (0 - 5) | 3 (1 - 6) | < 0.001c |
Registered patients | 23 (12 - 36) | 54 (3 - 75) | 16 (5 - 27) | 0.060 |
Patients missed for registration1 | 35 (10 - 81) | Unknown | Unknown | Â |
Inclusions (n per month) | 1.03 (0.43 - 2.21) | 0.14 (0.00 - 0.28) | 0.31 (0.09 - 0.62) | < 0.001d |
Total patients (n per month) | 2.49 (1.60 - 3.64) | 2.76 (0.60 - 8.75) | 1.96 (1.11 - 3.75) | 0.574 |
Proportion inclusions (% of total) | 34.4 (23.8 - 62.6) | 3.93 (0.00 - 13.2) | 16.7 (2.50 - 31.3) | 0.001e |
Proportion patients that were missed for registration of total1 (%) | 57.4 (32.2 - 65.2) | Unknown | Unknown | Â |
Completed follow-ups (%) | 82.6 (80.0 - 84.6) | 83.5 (72.7 - 95.2) | 70.0 (60.0 - 88.1) | 0.217 |
Follow-ups in window (%) | 77.1 (71.0 - 82.2) | 85.9 (81.0 - 95.0) | 85.7 (70.0 - 100.0) | 0.073 |